Caveolin 1 (Cav-1) and actin-related protein 2/3 complex, subunit 1B (ARPC1B) expressions as prognostic indicators for oral squamous cell carcinoma (OSCC)

Abstract

Caveolin-1 (Cav-1) and Actin-Related Protein 2/3 Complex, Subunit 1B (ARPC1B) have been implicated in various human cancers, yet its role in tumorigenesis remains controversial. Therefore, this study aims to determine the protein expression of these two genes in oral squamous cell carcinomas (OSCCs) and to evaluate the clinical and prognostic impact of these genes in OSCC. Protein expressions of these two genes were determined by immunohistochemistry technique. The association between Cav-1 and ARPC1B with clinico-pathological parameters was evaluated by Chi-square test (or Fisher exact test where appropriate). Correlation between the protein expressions of these 2 genes with survival was analyzed using Kaplan-Meier and Cox regression models. Cav-1 and ARPC1B were found to be significantly over-expressed in OSCC compared to normal oral mucosa (p = 0.002 and p = 0.033, respectively). Low level of ARPC1B protein expression showed a significant correlation with lymph node metastasis (LNM) (p = 0.010) and advanced tumor staging (p = 0.003). Kaplan-Meier survival analyses demonstrated that patients with over-expression of Cav-1 protein were associated with poor prognosis (p = 0.030). Adjusted multivariate Cox regression model revealed that over-expression of Cav-1 remained as an independent significant prognostic factor for OSCC (HRR = 2.700, 95 % CI 1.013-7.198, p = 0.047). This study demonstrated that low-expression of ARPC1B is significantly associated with LNM and advanced tumor staging whereas high expression of Cav-1 can be a prognostic indicator for poor prognosis in OSCC patients.

Expression and significance of caveolin‑1 in hepatitis B virus‑associated hepatocellular carcinoma

“…Previous results have demonstrated that Cav-1 is a growth-inhibitory protein that may act as a tumor suppressor (8,9). Cav-1 expression is downregulated in some forms of cancer, including mesenchymal tumors and sarcomas (8,10); however, in other cancer types; for example, oral squamous cell carcinoma, Cav-1 expression is high (11,12). These findings suggest that Cav-1 has multiple actions in human cancer cells.…”

Loss of the Arp2/3 complex component ARPC1B causes platelet abnormalities and predisposes to inflammatory disease

“…The isoforms they encode have 68% amino acid sequence identity15 and both have six WD40 domain repeats predicted to form a β-propeller-fold316. ARPC1A has been implicated as a regulator of cell migration and invasion in pancreatic cancer14, while increased ARPC1B has been linked to oral squamous cell carcinoma17. Independent of its function in Arp2/3, ARPC1B has also been identified as a centrosomal protein involved in mitosis1819.…”

Marcadores imuno-histoquímicos de prognóstico e sobrevida dos pacientes com carcinoma epidermoide da cavidade oral: uma revisão sistemática

“…Dos estudos com baixo risco de viés, nenhum respondeu a todas as questões do MAStARI, isto é, 11 deles (Tsai et al, 2008;Liu et al, 2010;Bose et al, 2012;Klimowicz et al, 2012;Coutinho-Camillo et al, 2013;Grimm et al, 2013;Lee et al, 2014;Magnussen et al, 2014;Auzair et al, 2016;Fernández-Valle et al, 2016;Gissi et al, 2016) responderam de forma positiva a maioria das questões da avaliação qualitativa, ou seja, não responderam a uma única questão, e obtiveram o índice de 90,9% na escala do risco de viés. As questões não respondidas foram a 3 ou 7, isto é, fatores de confusão e motivos pela perda de seguimento.…”

“…A expressão imuno-histoquímica do Cav-1 e ARPC1B no carcinoma epidermoide oral foi avaliada quanto ao impacto no prognóstico da doença (Auzair et al, 2016). Os autores observaram que o Cav-1 e ARPC1B foram encontrados significativamente mais expressos no carcinoma epidermoide do que na mucosa oral normal.…”

“…Para esta revisão foram considerados como mais relevantes os marcadores estudados em pelo menos três artigos, como anteriormente feito na literatura (Almangush et al, 2017). (Chu et al, 2012;Bose et al, 2012;Klimowicz et al, 2012;Grimm et al, 2013b;Klimowicz et al, 2013;Rosado et al, 2013;Lee et al, 2014;Ravindran;Devaraj, 2015;Auzair et al, 2016;Gissi et al, 2016).…”